Symbiomix today announced it is accelerating plans for the commercial launch of Solosec™ (secnidazole) oral granules following the presentation of clinical results from the second pivotal trial for the treatment of bacterial vaginosis (BV) with the hiring of Taunia Markvicka, PharmD, MBA, as Chief Commercial Officer. Symbiomix had a significant presence at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting in Annapolis, Maryland this past weekend with both the oral data presentation and sponsorship of a panel discussion on emerging diagnosis and treatment recommendations for BV. In addition, the company announced that the U.S. Food and Drug Administration (FDA) issued conditional acceptance of the proprietary name Solosec™. Solosec™ was previously known as SYM-1219.